Open AccessTreatment of chronic heart failure with a very low dose of antibodies to C-fragment of type 1 angiotensin II receptor
Author(s) -
Т. М. Попонина,
Ye. S. Noll,
Yu. S. Poponina,
B. F. Portnyagin,
Н. М. Симонова
Publication year - 2009
Publication title -
bûlletenʹ sibirskoj mediciny
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 3
eISSN - 1819-3684
pISSN - 1682-0363
DOI - 10.20538/1682-0363-2009-4(2)-86-91
Subject(s) - ventricle , angiotensin ii , medicine , placebo , heart failure , contractility , receptor , angiotensin ii receptor type 1 , antibody , cardiology , pharmacology , immunology , pathology , alternative medicine
The open randomized placebo-controlled prospective study was conducted; we documented improvement of global contractility and diastolic function of left ventricle, clinical and psychological status in 60 patients with chronic heart failure receiving a very low dose of antibodies to C-end fragment to AT1 receptors of angiotensin II for 6 months (Cardosten). The drug was well-tolerated.